CC
DFTX

Caxton Corporation’s Definium Therapeutics DFTX Stock Holding History

Caxton Corporation’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,688
Closed -$210K – 10
2025
Q4 		$210K Sell
15,688
-11,323
-42% -$140K 4.91% 4
2025
Q3 		$318K Sell
27,011
-7,062
-21% -$65.9K 1.39% 4
2025
Q2 		$221K Hold
34,073
– – 2.24% 5
2025
Q1 		$199K Hold
34,073
– – 3.92% 4
2024
Q4 		$237K Hold
34,073
– – 1.43% 6
2024
Q3 		$194K Buy
34,073
+3,690
+12% +$25.7K 0.8% 6
2024
Q2 		$219K Buy
30,383
+1,318
+5% +$11.5K 1.11% 6
2024
Q1 		$273K Buy
+29,065
New +$166K 1.56% 7

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caxton Corporation's DFTX Position: Q1 2026 in Review

Caxton Corporation sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 15,688 shares — an estimated $210K sold.

Caxton Corporation first reported a position in DFTX in Q1 2024 and held it in 8 quarters. The position peaked at $318K in Q3 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Caxton Corporation reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Corporation sold 15,688 Definium Therapeutics shares in Q1 2026, an estimated $210K.
  • Caxton Corporation first reported a position in Definium Therapeutics in Q1 2024 and held it in 8 quarters.
  • Caxton Corporation's Definium Therapeutics position peaked at $318K in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.